Form 4 for BMY Bristol Myers Squibb
Accepted 2025-09-03 00:00:00 ET · period of report 2025-09-02 · accession 0000014272-25-000144 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-03 | 2025-09-02 | BMY | Elkins David V | EVP, CFO | S - Sale | $47.33 | -56.0K | 167.4K | -25% | -$2.65M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.10 par value | 2025-09-02 | S | D | 56,000 | $47.33 | 167,379 | D | — | — | (F1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. (F2) The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.075 to $47.820, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. |